# Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

> **NCT03519971** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 328 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Durvalumab
- **OTHER:** Placebo
- **DRUG:** Cisplatin/ Etoposide
- **DRUG:** Carboplatin/ Paclitaxel
- **DRUG:** Pemetrexed/ Cisplatin
- **DRUG:** Pemetrexed/ Carboplatin
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT03519971
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-03-29
- **Primary completion:** 2023-09-07
- **Final completion:** 2025-12-01
- **Target enrollment:** 328 (ACTUAL)
- **Last updated:** 2025-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03519971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03519971, "Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03519971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*